Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014)

被引：13

作者：

Daniels, Benjamin ^{[1
]}

Kiely, Belinda E. ^{[2
]}

Houssami, Nehmat ^{[3
]}

Lord, Sarah J. ^{[2
,4
]}

Dobbins, Timothy ^{[5
]}

Lu, Christine Y. ^{[6
,7
]}

Ward, Robyn L. ^{[8
]}

Pearson, Sallie-Anne ^{[1
]}

机构：

[1] Univ New South Wales, Med Policy Res Unit, Ctr Big Data Res Hlth, Sydney, NSW 2052, Australia

[2] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2050, Australia

[3] Univ Sydney, Sydney Sch Publ Hlth, Sydney Med Sch, Sydney, NSW 2050, Australia

[4] Univ Notre Dame Australia, Sch Med, Sydney, NSW 2050, Australia

[5] Univ New South Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia

[6] Harvard Med Sch, Dept Populat Med, Boston, MA 02215 USA

[7] Harvard Pilgrim Hlth Care Inst, Boston, MA 02215 USA

[8] Univ Queensland, Brisbane, Qld 4072, Australia

来源：

BRITISH JOURNAL OF CANCER | 2018年 / 118卷 / 03期

基金：

澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;

关键词：

trastuzumab; breast cancer; metastatic; adjuvant; neoadjuvant; overall survival; population-based; routinely collected data; ADJUVANT TRASTUZUMAB; CLINICAL-OUTCOMES; PERTUZUMAB; CHEMOTHERAPY; RETREATMENT; DOCETAXEL; EMTANSINE; PATTERNS; THERAPY; FAILURE;

D O I：

10.1038/bjc.2017.405

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Background: Patients treated with (neo) adjuvant trastuzumab who relapse and receive trastuzumab for metastatic breast cancer (MBC) are a growing population with little outcome data given their exclusion from most clinical trials. We aim to estimate survival outcomes for this trastuzumab 'pre-treated' population. Methods: Population-based study of Australian women receiving trastuzumab for HER2-positive MBC between 2006 and 2014, who also received (neo) adjuvant trastuzumab. We used Kaplan-Meier methods to estimate the following: overall survival (OS) from initiation of trastuzumab for MBC; duration of trastuzumab for MBC; and time from last (neo) adjuvant trastuzumab to first trastuzumab for MBC. Results: Of 3199 patients dispensed trastuzumab for MBC, 634 (20%) had received (neo) adjuvant traztuzumab. Pre-treated patients had a median (interquartile range) OS of 21.8 months (10.9-51.6), trastuzumab duration of 12.8 months (4.7-17.5), and time from last (neo) adjuvant trastuzumab to first trastuzumab for MBC of 15.6 months (6.5-28.6). Median OS for patients initiating trastuzumab <12 months and >= 12 months from their last (neo) adjuvant trastuzumab were 17.1 months and 24.8 months, respectively. Conclusions: Patients starting trastuzumab for MBC following (neo) adjuvant trastuzumab had a median treatment duration of 1 year and OS of almost 2 years. These data help inform clinical practice and service planning for this under-researched population.

引用

页码：441 / 447

页数：7

共 22 条

[1]

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [J].

Baselga, Jose ;

Cortes, Javier ;

Kim, Sung-Bae ;

Im, Seock-Ah ;

Hegg, Roberto ;

Im, Young-Hyuck ;

Roman, Laslo ;

Pedrini, Jose Luiz ;

Pienkowski, Tadeusz ;

Knott, Adam ;

Clark, Emma ;

Benyunes, Mark C. ;

Ross, Graham ;

Swain, Sandra M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) :109-119

[2]

1st International consensus guidelines for advanced breast cancer (ABC 1) [J].

Cardoso, F. ;

Costa, A. ;

Norton, L. ;

Cameron, D. ;

Cufer, T. ;

Fallowfield, L. ;

Francis, P. ;

Gligorov, J. ;

Kyriakides, S. ;

Lin, N. ;

Pagani, O. ;

Senkus, E. ;

Thomssen, C. ;

Aapro, M. ;

Bergh, J. ;

Di Leo, A. ;

El Saghir, N. ;

Ganz, P. A. ;

Gelmon, K. ;

Goldhirsch, A. ;

Harbeck, N. ;

Houssami, N. ;

Hudis, C. ;

Kaufman, B. ;

Leadbeater, M. ;

Mayer, M. ;

Rodger, A. ;

Rugo, H. ;

Sacchini, V. ;

Sledge, G. ;

van't Veer, L. ;

Viale, G. ;

Krop, I. ;

Winer, E. .

BREAST, 2012, 21 (03) :242-252

[3]

<bold>Observational study evaluating resource utilization among </bold>metastatic renal cell carcinoma patients treated with mTOR inhibitors in the outpatient community-based setting. [J].

Chen, C. ;

Gruschkus, S. K. ;

Liu, Z. ;

Vogelzang, N. J. ;

Forsyth, M. T. ;

Lopez, W. ;

Hutson, T. E. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[4]

Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort [J].

Daniels, Benjamin ;

Lord, Sarah J. ;

Kiely, Belinda E. ;

Houssami, Nehmat ;

Haywood, Philip ;

Lu, Christine Y. ;

Ward, Robyn L. ;

Pearson, Sallie-Anne .

BMJ OPEN, 2017, 7 (01)

[5]

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial [J].

Harbeck, Nadia ;

Huang, Chiun-Sheng ;

Hurvitz, Sara ;

Yeh, Dah-Cherng ;

Shao, Zhimin ;

Im, Seock-Ah ;

Jung, Kyung Hae ;

Shen, Kunwei ;

Ro, Jungsil ;

Jassem, Jacek ;

Zhang, Qingyuan ;

Im, Young-Hyuck ;

Wojtukiewicz, Marek ;

Sun, Qiang ;

Chen, Shin-Cheh ;

Goeldner, Rainer-Georg ;

Uttenreuther-Fischer, Martina ;

Xu, Binghe ;

Piccart-Gebhart, Martine .

LANCET ONCOLOGY, 2016, 17 (03) :357-366

[6]

Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Relapsing Post-Adjuvant Trastuzumab: Pattern of Recurrence, Treatment and Outcome [J].

Krell, Jonathan ;

James, Colin R. ;

Shah, Deep ;

Gojis, Ondrej ;

Lim, Adrian ;

Riddle, Pippa ;

Ahmad, Riz ;

Makris, Andreas ;

Cowdray, Andrew ;

Chow, Angela ;

Babayev, Tamerlan ;

Madden, Peter ;

Leonard, Robert ;

Cleator, Susan ;

Palmieri, Carlo .

CLINICAL BREAST CANCER, 2011, 11 (03) :153-160

[7]

Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study [J].

Lambertini, Matteo ;

Ferreira, Arlindo R. ;

Poggio, Francesca ;

Puglisi, Fabio ;

Bernardo, Antonio ;

Montemurro, Filippo ;

Poletto, Elena ;

Pozzi, Emma ;

Rossi, Valentina ;

Risi, Emanuela ;

Lai, Antonella ;

Zanardi, Elisa ;

Sini, Valentina ;

Ziliani, Serena ;

Minuti, Gabriele ;

Mura, Silvia ;

Grasso, Donatella ;

Fontana, Andrea ;

Del Mastro, Lucia .

ONCOLOGIST, 2015, 20 (08) :880-889

[8]

Trastuzumab Retreatment after Relapse on Adjuvant Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Final Results of the Retreatment after Herceptin Adjuvant Trial [J].

Lang, I. ;

Bell, R. ;

Feng, F. Y. ;

Lopez, R. I. ;

Jassem, J. ;

Semiglazov, V. ;

Al-Sakaff, N. ;

Heinzmann, D. ;

Chang, J. .

CLINICAL ONCOLOGY, 2014, 26 (02) :81-89

[9]

Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience [J].

Metzger-Filho, Otto ;

de Azambuja, Evandro ;

Procter, Marion ;

Krieguer, Magalie ;

Smiths, Ian ;

Baselga, Jose ;

Cameron, David ;

Untch, Michael ;

Jackisch, Christian ;

Bell, Richard ;

Gianni, Luca ;

Goldhirsch, Aron ;

Piccart, Martine ;

Gelber, Richard D. .

BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (01) :127-132

[10]

Effect of Adjuvant/Neoadjuvant Trastuzumab on Clinical Outcomes in Patients With HER2-Positive Metastatic Breast Cancer [J].

Murthy, Rashmi K. ;

Varma, Ankur ;

Mishra, Priyankana ;

Hess, Kenneth R. ;

Young, Elliana ;

Murray, James L. ;

Koenig, Kimberly H. ;

Moulder, Stacy L. ;

Melhem-Bertrandt, Amal ;

Giordano, Sharon H. ;

Booser, Daniel ;

Valero, Vicente ;

Hortobagyi, Gabriel N. ;

Esteva, Francisco J. .

CANCER, 2014, 120 (13) :1932-1938

← 1 2 3 →